The year in heart failure

Journal of the American College of Cardiology

Volumn 46, Issue 11, 2005, Pages 2125-2133

  Tang, W H Wilson ^a   Francis, Gary S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CELACADE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENOXIMONE; HYDRALAZINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; INSULIN SENSITIZING AGENT; LEVOSIMENDAN; METFORMIN; METOPROLOL SUCCINATE; N(G) METHYLARGININE; NESIRITIDE; NITRATE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; OXIPURINOL; PEPTIDE DERIVATIVE; ROSUVASTATIN; TEZOSENTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT; XANTHINE OXIDASE INHIBITOR;

ACUTE HEART INFARCTION; ANEMIA; ARTERY CATHETERIZATION; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONGESTIVE CARDIOMYOPATHY; DEFIBRILLATOR; DEPRESSION; DEVICE; DIABETES MELLITUS; DRUG FATALITY; DRUG HYPERSENSITIVITY; GENE EXPRESSION PROFILING; HEART FAILURE; HEART HEMODYNAMICS; HEART MUSCLE BIOPSY; HEART RHYTHM; HUMAN; KIDNEY FUNCTION; META ANALYSIS; NEPHROTOXICITY; ORGANIZATION; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY ARTERY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC PACING, ARTIFICIAL; CARDIOGRAPHY, IMPEDANCE; CARDIOMYOPATHY, DILATED; CHRONIC DISEASE; CLINICAL TRIALS; COMORBIDITY; DISEASE MANAGEMENT; ENOXIMONE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; KIDNEY DISEASES; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PACEMAKER, ARTIFICIAL; PHOSPHODIESTERASE INHIBITORS; PRACTICE GUIDELINES; RECEPTORS, ANGIOTENSIN; XANTHINE OXIDASE;

EID: 28244464421     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.10.018     Document Type: Review

References (74)

1. M.M. Kittleson, S.Q. Ye, R.A. Irizarry Identification of a gene expression profile that differentiates between ischemic and nonischemic cardiomyopathy Circulation 110 2004 3444 3451
2. U. Kuhl, M. Pauschinger, M. Noutsias High prevalence of viral genomes and multiple viral infections in the myocardium of adults with " idiopathic" left ventricular dysfunction Circulation 111 2005 887 893
3. U. Lotze, R. Egerer, C. Tresselt Frequent detection of parvovirus B19 genome in the myocardium of adult patients with idiopathic dilated cardiomyopathy Med Microbiol Immunol (Berl) 193 2004 75 82
4. R.T. Murphy, J. Mogensen, A. Shaw, T. Kubo, S. Hughes, W.J. McKenna Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy Lancet 363 2004 371 372
5. E. Villard, L. Duboscq-Bidot, P. Charron Mutation screening in dilated cardiomyopathy prominent role of the beta myosin heavy chain gene Eur Heart J 26 2005 794 803
6. N.G. Mahon, R.T. Murphy, C.A. MacRae, A.L. Caforio, P.M. Elliott, W.J. McKenna Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease Ann Intern Med 143 2005 108 115
7. J.O. O'Neill, C.E. Bott-Silverman, A.T. McRae 3rd B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure Am Heart J 149 2005 363 369
8. H. Dokainish, W.A. Zoghbi, N.M. Lakkis Optimal noninvasive assessment of left ventricular filling pressures a comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters Circulation 109 2004 2432 2439
9. P.R. Forfia, S.P. Watkins, J.E. Rame, K.J. Stewart, E.P. Shapiro Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit J Am Coll Cardiol 45 2005 1667 1671
10. L. Binder, B. Pieske, M. Olschewski N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism Circulation 112 2005 1573 1579
11. M.S. Sabatine, D.A. Morrow, J.A. de Lemos Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia J Am Coll Cardiol 44 2004 1988 1995
12. H. Tsuji, N. Nishino, Y. Kimura Haemoglobin level influences plasma brain natriuretic peptide concentration Acta Cardiol 59 2004 527 531
13. M. Weber, T. Dill, R. Arnold N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris Am Heart J 148 2004 612 620
14. P.M. McKie, J.C. Burnett Jr B-type natriuretic peptide as a biomarker beyond heart failure speculations and opportunities Mayo Clin Proc 80 2005 1029 1036
15. P. Jourdain, F. Funck, P. Gueffet Benefits of BNP plasma levels for optimizing therapy the systolic heart failure treatment supported by BNP multicenter randomised trial (STARS-BNP) (abstr) J Am Coll Cardiol 45 Suppl A 2005 3A
16. M.P. Hudson, C.M. O'Connor, W.A. Gattis Implications of elevated cardiac troponin T in ambulatory patients with heart failure a prospective analysis Am Heart J 147 2004 546 552
17. I.S. Anand, R. Latini, V.G. Florea C-reactive protein in heart failure prognostic value and the effect of valsartan Circulation 112 2005 1428 1434
18. J. George, S. Patal, D. Wexler Circulating erythropoietin levels and prognosis in patients with congestive heart failure comparison with neurohormonal and inflammatory markers Arch Intern Med 165 2005 1304 1309
19. L.L. Ng, I.W. Loke, R.J. O'Brien, I.B. Squire, J.E. Davies Plasma urocortin in human systolic heart failure Clin Sci (Lond) 106 2004 383 388
20. C. Kistorp, J. Faber, S. Galatius Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure Circulation 112 2005 1756 1762
21. C. Binanay, R.M. Califf, V. Hasselblad Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness the ESCAPE trial JAMA 294 2005 1625 1633
22. Nohra A, Shah MR, Hill JA, Stevenson LW. Effect of empiric versus PAC-guided therapy on renal function in patients hospitalized with decompensated heart failure. Presented at: Heart Failure Society of America 2005 Annual Scientific Meeting; September 18-21, 2005; Boca Raton, FL: abstract 339.
23. Bourge R, Abraham WT, Aaron MF. Chronicle Offers Management to Patients With Advanced Signs and Symptoms of Heart Failure (COMPASS-HF): ambulatory hemodynamic guided management of heart failure. Presented at: American College of Cardiology Annual Scientific Session 2005; March 6-9, 2005; Orlando, FL: Late Breaking Clinical Trials II.
24. Abraham WT, Trupp RJ, Mehra MR, et al. Prospective Evaluation and Identification of Decompensation by ICG Test (PREDICT). Presented at: Heart Failure Society of America 8th Annual Scientific Meeting; September 13, 2004; Toronto, Canada.
25. C.M. Yu, L. Wang, E. Chau Intrathoracic impedance monitoring in patients with heart failure correlation with fluid status and feasibility of early warning preceding hospitalization Circulation 112 2005 841 848
26. A.D. Galbreath, R.A. Krasuski, B. Smith Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure Circulation 110 2004 3518 3526
27. C. Kimmelstiel, D. Levine, K. Perry Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network the SPAN-CHF trial Circulation 110 2004 1450 1455
28. J.G. Cleland, A.A. Louis, A.S. Rigby, U. Janssens, A.H. Balk Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death the Trans-European Network-Home-Care Management System (TEN-HMS) study J Am Coll Cardiol 45 2005 1654 1664
29. T.M. Koelling, M.L. Johnson, R.J. Cody, K.D. Aaronson Discharge education improves clinical outcomes in patients with chronic heart failure Circulation 111 2005 179 185
30. M.J. Radford, J.M. Arnold, S.J. Bennett ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Heart Failure Clinical Data Standards): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Failure Society of America Circulation 112 2005 1888 1916
31. R.O. Bonow, S. Bennett, D.E. Casey Jr. ACC/AHA clinical performance measures for adults with chronic heart failure a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America J Am Coll Cardiol 46 2005 1144 1178
32. G.C. Fonarow, C.W. Yancy, J.T. Heywood Adherence to heart failure quality-of-care indicators in US hospitals analysis of the ADHERE registry Arch Intern Med 165 2005 1469 1477
33. M. Komajda, P. Lapuerta, N. Hermans Adherence to guidelines is a predictor of outcome in chronic heart failure the MAHLER survey Eur Heart J 26 2005 1653 1659
34. F.A. Masoudi, S.E. Inzucchi, Y. Wang, E.P. Havranek, J.M. Foody, H.M. Krumholz Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure an observational study Circulation 111 2005 583 590
35. S.E. Inzucchi, F.A. Masoudi, Y. Wang Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction insights from the National Heart Care Project Diabetes Care 28 2005 1680 1689
36. I. Anand, J.J. McMurray, J. Whitmore Anemia and its relationship to clinical outcome in heart failure Circulation 110 2004 149 154
37. I.S. Anand, M.A. Kuskowski, T.S. Rector Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure results from Val-HeFT Circulation 112 2005 1121 1127
38. E.P. Havranek, J.A. Spertus, F.A. Masoudi, P.G. Jones, J.S. Rumsfeld Predictors of the onset of depressive symptoms in patients with heart failure J Am Coll Cardiol 44 2004 2333 2338
39. G. Zuccala, E. Marzetti, M. Cesari Correlates of cognitive impairment among patients with heart failure results of a multicenter survey Am J Med 118 2005 496 502
40. S.A. Hunt, W.T. Abraham, M.H. Chin ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) J Am Coll Cardiol 46 2005 1116 1143
41. K. Swedberg, J. Cleland, H. Dargie Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology Eur Heart J 26 2005 1115 1140
42. M.S. Nieminen, M. Bohm, M.R. Cowie Executive summary of the guidelines on the diagnosis and treatment of acute heart failure the Task Force on Acute Heart Failure of the European Society of Cardiology Eur Heart J 26 2005 384 416
43. S.D. Solomon, H. Skali, N.S. Anavekar Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction Circulation 111 2005 3411 3419
44. Colucci W. Reversal of Ventricular Remodeling with Toprol-XL (REVERT) study. Presented at: 9th Annual Scientific Meeting of the Heart Failure Society of America, September 18-21, 2005, Boca Raton, FL: Late Breaking Clinical Trials.
45. K. Sliwa, G.R. Norton, N. Kone Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure J Am Coll Cardiol 44 2004 1825 1830
46. R. Willenheimer, D.J. van Veldhuisen, B. Silke Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III Circulation 112 2005 2426 2435
47. A.L. Taylor, S. Ziesche, C. Yancy Combination of isosorbide dinitrate and hydralazine in blacks with heart failure N Engl J Med 351 2004 2049 2057
48. M.D. Flather, M.C. Shibata, A.J. Coats Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur Heart J 26 2005 215 225
49. Dzavik V, Cotter G, Farkouh ME, et al. Effect of nitric oxide synthase inhibition on hemodynamics and outcome of patients with acute myocardial infarction complicated by cardiogenic shock: a Phase 2 dose-ranging study. Presented at: American Heart Association Scientific Session; November 18, 2004; New Orleans, LA.
50. J.D. Sackner-Bernstein, H.A. Skopicki, K.D. Aaronson Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure Circulation 111 2005 1487 1491
51. J.D. Sackner-Bernstein, M. Kowalski, M. Fox, K. Aaronson Short-term risk of death after treatment with nesiritide for decompensated heart failure a pooled analysis of randomized controlled trials JAMA 293 2005 1900 1905
52. MedWatch Safety Alert: Natrecor (nesiritide). http://www.fda.gov/ medwatch/safety/2005/natrecor2_DHCP.htm. Accessed September 15, 2005.
53. McMurray JV, Teerlink JR, Bourge B. Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies (VERITAS): two multi-center, double-blind, placebo-controlled, parallel-group trials assessing the efficacy, safety, and tolerability of tezosentan in acute heart failure. Presented at: American College of Cardiology Annual Scientific Session 2005, March 6-9, Orlando, FL: Late Breaking Clinical Trials II.
54. Feldman AM. EMOTE: Oral enoximone in intravenous inotrope-dependent subjects. Presented at: Heart Failure Society of America 8th Annual Scientific Meeting, September 13, 2004; Toronto, Canada; Late-Breaking Clinical Trials.
55. Metra M. ESSENTIAL: the Studies of Oral Enoximone Therapy in Advanced Heart Failure. Presented at: European Society of Cardiology Congress 2005; September 5-8, 2005; Stockholm, Sweden: Late Breaking Clinical Trials.
56. A. Mebazaa, D. Barraud, S. Welschbillig Randomized clinical trials with levosimendan Am J Cardiol 96 2005 74 79
57. R.S. Freudenberger, R.P. Schwarz Jr., J. Brown Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III-IV congestive heart failure Expert Opin Investig Drugs 13 2004 1509 1516
58. G. Torre-Amione, F. Sestier, B. Radovancevic, J. Young Effects of a novel immune modulation therapy in patients with advanced chronic heart failure results of a randomized, controlled, phase II trial J Am Coll Cardiol 44 2004 1181 1186
59. J.G. Ray, Y. Gong, K. Sykora, J.V. Tu Statin use and survival outcomes in elderly patients with heart failure Arch Intern Med 165 2005 62 67
60. Mann D. Results of a multicenter randomized clinical trial for the assessment of a cardiac support device (CSD) in patients with heart failure. Presented at: American Heart Association Scientific Sessions 2004; November 7-10, 2004; New Orleans, LA.
61. C.L. Athanasuleas, G.D. Buckberg, A.W. Stanley Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation J Am Coll Cardiol 44 2004 1439 1445
62. A.H. Wu, K.D. Aaronson, S.F. Bolling, F.D. Pagani, K. Welch, T.M. Koelling Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction J Am Coll Cardiol 45 2005 381 387
63. N. Dib, R.E. Michler, F.D. Pagani Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy four-year follow-up Circulation 112 2005 1748 1755
64. V. Schachinger, B. Assmus, M.B. Britten Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction final one-year results of the TOPCARE-AMI trial J Am Coll Cardiol 44 2004 1690 1699
65. T. Siminiak, D. Fiszer, O. Jerzykowska Percutaneous trans-coronary-venous transplantation of autologous skeletal myoblasts in the treatment of post-infarction myocardial contractility impairment the POZNAN trial Eur Heart J 26 2005 1188 1195
66. H.F. Dohmann, E.C. Perin, C.M. Takiya Transendocardial autologous bone marrow mononuclear cell injection in ischemic heart failure postmortem anatomicopathologic and immunohistochemical findings Circulation 112 2005 521 526
67. J.G. Cleland, J.C. Daubert, E. Erdmann The effect of cardiac resynchronization on morbidity and mortality in heart failure N Engl J Med 352 2005 1539 1549
68. G. Nichol, P. Kaul, E. Huszti, J.F. Bridges Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure Ann Intern Med 141 2004 343 351
69. C.M. Yu, G.B. Bleeker, J.W. Fung Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy Circulation 112 2005 1580 1586
70. C.M. Yu, W.T. Abraham, J. Bax Predictors of response to cardiac resynchronization therapy (PROSPECT)-study design Am Heart J 149 2005 600 605
71. K.R. Kareti, J.R. Chiong, S.S. Hsu, A.B. Miller Congestive heart failure and atrial fibrillation rhythm versus rate control J Card Fail 11 2005 164 172
72. V.E. Hagens, H.J. Crijns, D.J. Van Veldhuisen Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure results from the RAte Control versus Electrical cardioversion (RACE) study Am Heart J 149 2005 1106 1111
73. L.F. Hsu, P. Jais, P. Sanders Catheter ablation for atrial fibrillation in congestive heart failure N Engl J Med 351 2004 2373 2383
74. M.S. Chen, N.F. Marrouche, Y. Khaykin Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function J Am Coll Cardiol 43 2004 1004 1009